Change over period
From:
To:
Zoom:
- 3M
- 6M
- YTD
- 1Y
- 3Y
- 5Y
- 10Y
- 15Y
- 20Y
- Max
Cellectar Biosciences Inc
NASDAQ CLRB
Data sourced from
and
and
Download Data
Cellectar Biosciences Inc Price to Book Ratio (P/B) on June 03, 2024: 4.04
Cellectar Biosciences Inc Price to Book Ratio (P/B) is 4.04 on June 03, 2024, a 47.88% change year over year. The price to book ratio compares the market price per share of a company's stock to its book value per share. It is calculated by dividing the market capitalization by the shareholders' equity minus treasury stock, divided by the number of outstanding shares. This ratio provides insights into how the market values a company relative to its book value. A ratio above 1 indicates the market values the company more than its book value, suggesting positive market sentiment.
-
Cellectar Biosciences Inc 52-week high Price to Book Ratio (P/B) is 4.60 on May 15, 2024, which is 13.90% above the current Price to Book Ratio (P/B).
-
Cellectar Biosciences Inc 52-week low Price to Book Ratio (P/B) is -94.92 on April 02, 2024, which is -2,448.61% below the current Price to Book Ratio (P/B).
-
Cellectar Biosciences Inc average Price to Book Ratio (P/B) for the last 52 weeks is -22.59.
Don’t Miss A Beat
Looking to stay ahead of the competition and stay informed? Receive your daily dose of market news, trends, and analysis to kickstart your day and stay up-to-date.
NASDAQ: CLRB
| CEO | Mr. James V. Caruso |
| IPO Date | Nov. 10, 2005 |
| Location | United States |
| Headquarters | 100 Campus Drive, Florham Park, NJ, United States, 07932 |
| Employees | 20 |
| Sector | Healthcare |
| Industry | Biotechnology |
Description
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.
Key trends
Similar companies
Pulmatrix Inc
NA
NA
NextCure Inc
NA
NA
StockViz Staff
September 20, 2024
Any question? Send us an email